PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

EHA2023 Hybrid Congress

June, 8-11 Frankfurt

N. Poster

Poster title

Applicant name

Status


P-0315	TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL	Rathana Kim	Received

P-0317	ANTI-LEUKEMIA ACTIVITY OF CD70-DIRECTED IMMUNOTHERAPY IN B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Qian Sun	Received

P-0319	IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION	Lucien Courtois	Received

P-0320	A NOVEL MAMMALIAN L-ASPARAGINASE WITH NO L-GLUTAMINASE ACTIVITY IS HIGHLY EFFICACIOUS AGAINST T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN VIVO	Maaike Van Trimpont	Received

P-0321	TNF-MEDIATED CELL DEATH: AN ACTIONABLE TARGET FOR IMMUNOTHERAPY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Marie-Emilie Dourthe	Received

P-0322	DECIPHERING THE UNDERLYING MOLECULAR COMPLEXITY OF THE IKZF1PLUS SIGNATURE	Jonathan Lühmann	Received

P-0325	APPLICATIONS OF HIGH-THROUGHPUT DRUG SCREENING AS DRUG REPURPOSING STRATEGY FOR POOR OUTCOME SUBGROUPS OF PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Athanasios Oikonomou	Received

P-0326	A DUAL ROLE FOR PSIP1 IN T-ALL	Lisa Demoen	Received

P-0327	LOSS OF POLYCOMB REPRESSIVE COMPLEX 2 FUNCTION CAUSES ASPARAGINASE RESISTANCE IN T-ACUTE LYMPHOBLASTIC LEUKAEMIA THROUGH DECREASED WNT PATHWAY ACTIVITY	Jonathan Bond	Received

P-0328	CHARACTERIZATION OF A DUX4-R INHIBITOR AS A POSSIBLE TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA	Mara Salomè	Received

P-0329	HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN´S ONCOLOGY GROUP TRIAL AALL1231	Margot Roeten	Received

P-0332	LIN28B: AN IMPORTANT ONCO-FETAL GENE IN INFANT ACUTE LYMPHOBLASTIC LEUKAEMIA	Rebecca Ling	Received

P-0336	PREDICTIVE SCORES FOR RELAPSE AND PROGRESSION DISEASE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS BASED ON OPTICAL GENOME MAPPING TECHNOLOGY	Jorge Garcia Martinez	Received

P-0337	IKZF1 DELETIONS IN B-ALL: FROM ITS GENETIC BASIS TO DIAGNOSTIC ENHANCEMENT	Bruno A. Lopes	Received

P-0338	SLC7A11 PROMOTES ARGININE BIOSYNTHESIS IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMMUNOTHERAPEUTIC POTENTIAL	Jianda Hu	Received

P-0342	RAS PATHWAY ACTIVATION REMODELS THE BONE MARROW MICROENVIRONMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA	Mauricio Ferrao Blanco	Received

P-0343	MUTATIONS IN GENES RELATED TO EPIGENETIC REGULATION, TREATMENT RESISTANCE AND IKZF1 PLUS PROFILE IDENTIFY RELAPSE PROFILES IN B-ALL.	Josgrey Del Valle Navas Acosta	Received

P-0345	IN SILICO DRUG REPURPOSING STUDY AND MOLECULAR SIGNATURE IDENTIFICATION ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	Yagmur Kiraz Durmaz	Received

P-346	DECIPHER STRUCTURAL ABERRATIONS OF THE PAX5 GENE AND THEIR CORRELATION WITH DIAGNOSTIC CLASSIFICATION AND TREATMENT OUTCOME IN B CELL LYMPHOBLASTIC LEUKEMIA	Tong Wang	Received

P-0347	PHARMACOLOGICAL EZRIN INHIBITION REDUCES GROWTH, ADHESION, MIGRATION AND REGULATE GENE RELATED TO APOPTOSIS AND CELL CYCLE IN ACUTE LYMPHOBLASTIC LEUKAEMIA	Jean Carlos Lipreri Da Silva	Received

P-0348	GENOMIC CHARACTERIZATION OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC PATIENTS UNDERGOING CAR-T TREATMENT IN A SINGLE CENTER	Elena Esperanza Cebollada	Received

P-0349	CRISPR/CAS9 SCREEN IDENTIFIES PTPMT1 AS AN ESSENTIAL GENE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PROLIFERATION	Jianda Hu	Received

P-0351	PROTEASOME INHIBITORS INDUCE DNA DAMAGE AND MITOTIC CATASTROPHE IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) VIA AUTOPHAGY-MEDIATED DEGRADATION OF WEE1	Chun Fung Sin	Received

P-0354	MULTI-INSTITUTIONAL STUDY EVALUATING THE IMPACT ON SURVIVAL OF NEWER TREATMENT COMBINATIONS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Talha Badar	Received

P-0356	PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)	Kenneth Jacobs	Received

P-0357	DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Xiaowen Tang	Received

P-0358	HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY	Nicholas Short	Received

P-0360	MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)	Prashant Tembhare	Received

P-0361	HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE	Andreas Ochs	Received

P-0363	A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL	Weiyang Liu	Received

P-0364	A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Fadi Haddad	Received

P-0365	SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY	Shaun Fleming	Received

P-0366	ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?	Janine Stutterheim	Received

P-0369	DONOR-DERIVED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL	Gui Li	Received

P-0370	EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULTS PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH T315I MUTATION AND RELAPSED/REFRACTORY DISEASE	Weiyang Liu	Received

P-0373	UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Fadi Haddad	Received

P-0375	INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA	Sabine Kayser	Received

P-0377	A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	Fadi Haddad	Received

P-0378	CHEMO-FREE TREATMENT OF VAF INDUCE A EARLY AND DEEP MOLECULAR RESPONSEIN IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA : A PROSPECTIVE, SINGLE ARM, PHASE II STUDY	Xiaowen Tang	Received

P-0379	PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL	Fadi Haddad	Received

P-0381	FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE	Elena Maio	Received

P-0385	COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE	Maria Agustina Perusini	Received

P-0386	COMPARISON OF THE PHARMACOKINETICS OF THE LIQUID AND THE LYOPHILIZED FORMULATIONS OF PEGASPARGASE IN THE TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	Alexander Karachunskiy	Received

P-0388	THERAPY OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON PEDIATRIC-INSPIRED PROTOCOLS IN THE CZECH REPUBLIC IN 2007–2020	Jan Horacek	Received

P-0392	FEATURES AND TREATMENT OF PATIENTS WITH T(8;14)(Q24;Q11) / TCRA/D::MYC TRANSLOCATED T ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/LBL)	Xian Zhang	Received

P-0394	FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Kaibo Zhu	Received

P-0395	PREDICTING SURVIVAL AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA: DEVELOPMENT AND VALIDATION OF THE SAVED MODEL	Xiao-Hui Zhang	Received

P-0398	HIGH-RISK CHILDHOOD AND ADOLESCENT AND YOUNG ADULTS ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH THE EORTC 58951 PROTOCOL: RESULTS AND OUTCOME	Imen Frikha	Received

P-0400	COMPARISON OF MORPHOLOGICAL & MRD RESPONSE WITH DEXAMETHASONE VERSUS PREDNISOLONE IN BFM 2009 INDUCTION THERAPY IN PEDIATRIC AND AYA ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER STUDY FROM INDIA	Karthik Kumar	Received

P-0403	HIGH EXPRESSION OF STAT5 INDICATES POOR PROGNOSIS IN B CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Xiuli Xu	Received

P-0405	IN VITRO RESPONSE TO BCL-2 INHIBITION IN PEDIATRIC B PRECURSOR ALL WITH HIGH RISK CYTOGENETICS	Francesca Gottardi	Received

P-0406	INCIDENCE OF COMPLICATIONS OF HIGH-DOSE METHOTREXATE ADMINISTRATION IN ADULTS AND CHILDREN WITH HEMATOLOGIC CANCERS: PRELIMINARY RESULTS FROM A EUROPEAN REGISTRY	Scott Howard	Received

P-0407	MITOTIC FIDELITY IS A RESISTANCE MECHANISM TO DECITABINE IN MYELOID TUMORS.	Tomohiro Yabushita	Received

P-0408	COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX	Simon Renders	Received

P-0409	BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA	Ida Vänttinen	Received

P-410	COMBINING MENIN AND MEK INHIBITION TO TREAT CHILDREN WITH POOR PROGNOSTIC KMT2A-R RAS-MUTANT ACUTE LEUKEMIA	Nastassja Scheidegger	Received

P-412	TRANSCRIPTOMIC CLASSIFICATION, RISK STRATIFICATION AND THERAPY SELECTION IN AML	Jeppe Severens	Received

P-0414	PATIENT-DERIVED XENOGRAFT MODELS ARE THE LEADING STRATEGY TO IDENTIFY NEW AGENTS FOR PEDIATRIC ACUTE MYELOID LEUKEMIA	Ambra Da Ros	Received

P-0415	A COMPLEX INTERPLAY OF INTRA- AND EXTRACELLULAR FACTORS REGULATES THE OUTCOME OF FETAL- AND ADULT-DERIVED MLL-REARRANGED LEUKEMIA	Sudip Ghosh	Received

P-0416	DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE	Katherine Kelly	Received

P-0418	DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE	Megan Ruzomberka	Received

P-0421	TARGETED DISRUPTION OF HUMAN FLT3 ERADICATES LEUKEMIC STEM CELLS WITHOUT HARMING HEALTHY HEMATOPOIETIC STEM CELLS	Joana Araújo	Received

P-0422	TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA	Xining Yang	Received

P-0423	ACUTE MYELOID LEUKEMIA REPROGRAMS LIPID METABOLISM BY DOWNREGULATING CD36 EXPRESSION IN HEPATOCYTES.	Rebecca Maynard	Received

P-0425	A MULTIDIMENSIONAL AND SPATIAL ANALYSIS REVEALS DISTINCT IMMUNE PHENOTYPES AND SECONDARY LYMPHOID ORGAN-RESEMBLING STRUCTURES IN THE BONE MARROW OF PEDIATRIC ACUTE MYELOID LEUKEMIA	Joost Koedijk	Received

P-0427	CEBP/? CONTROLS A CORE DIFFERENTIATION PROGRAM PERTURBED IN HOX-INDUCED LEUKEMIA	Robert Slany	Received

P-0430	COMBINATORIAL ADAPTOR-MEDIATED TARGETING OF ACUTE MYELOID LEUKEMIA WITH CAR T-CELLS	Laura Volta	Received

P-0431	ACTIVATION OF MACROPHAGE STING ENHANCES PHAGOCYTOSIS OF ACUTE MYELOID LEUKAEMIA	Rebecca Maynard	Received

P-0432	VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL	Jesse Tettero	Received

P-0435	NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA	Claudia Tregnago	Received

P-0437	EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES	Noa Wijnen	Received

P-0439	RNA SEQUESTRATION IN P-BODIES PROMOTES LEUKEMIA ONSET AND PROGRESSION	Ludovica Proietti	Received

P-0440	ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML	Etienne Sollier	Received

P-0441	CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB	Steve Waye	Received

P-0442	DDX41 GERMLINE VARIANTS: POPULATION PREVALENCE, SIGNIFICANCE AND LEUKEMIC EVOLUTION	Sruthi Cheloor Kovilakam	Received

P-445	A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML	Francesca Sacco	Received

P-0446	COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING	Susanne Thieme	Received

P-0447	DECIPHERING THE MITOPHAGY RECEPTOR NETWORK IDENTIFIES A CRUCIAL ROLE FOR OPTINEURIN IN ACUTE MYELOID LEUKEMIA	Sebastian Koschade	Received

P-0448	PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML	Jesse Tettero	Received

P-0451	GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.	Anna Ferrari	Received

P-0455	RUNX1 DIRECTLY BINDS AND REGULATES THE TCF4 PROMOTER	Mylene Gerritsen	Received

P-0456	LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1	Ecmel Mehmetbeyoglu	Received

P-0460	ERK1/2 INHIBITION OVERCOMES RESSITANCE TO BCL2 INHIBITION IN ACUTE MYELOID LEUKEMIA BY IMPACT ON MITOCHONDRIAL DYNAMICS AND FUNCTION	Priyanka Sharma	Received

P-0461	THE FLT3 RECEPTOR IS INVOLVED IN THE ENDOPLASMIC RETICULUM HOMEOSTASIS AND GLUCOSE METABOLISM STATUS IN ACUTE MYELOID LEUKEMIA	Maria Turos Cabal	Received

P-0463	DATABASE GUIDED STRATEGY FOR THE CHARACTERIZATION OF LEUKEMIC STEM CELL IN ACUTE MYELOBLASTIC LEUKEMIA. IMPLICATIONS IN THE DIAGNOSIS AND PROGNOSIS OF THE DISEASE.	Paula Piñero	Received

P-0465	N-MYRISTOYLATION INHIBITION ABROGATES OXIDATIVE PHOSPHORYLATION TO TARGET ACUTE MYELOID LEUKEMIA STEM CELLS	Erwan Beauchamp	Received

P-0466	THE INTRINSICALLY DISORDERED TRANSCRIPTIONAL REGULATOR MN1 DEPENDS ON THE CHAPERONE DNAJB6B FOR ITS FULL TRANSFORMING POTENTIAL	Diego A Pereira-Martins	Received

P-0469	ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA	Dominic Fowler-Shorten	Received

P-0471	POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA	Wing Lam	Received

P-0472	SINGLE-CELL PROFILING REVEALS HETEROGENEITY OF EXPANDED PLASMACYTOID DENDRITIC CELLS IN ACUTE MYELOID LEUKEMIA	Juan Peng	Received

P-0473	CRISPR/CAS9 GENE EDITING CLARIFIES THE ROLE OF CD33 SNP RS12459419 IN GEMTUZUMAB OZOGAMICIN-MEDIATED CYTOTOXICITY	Shuki Oya	Received

P-0475	EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.	Lok Lam Ngai	Received

P-0476	AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA	Kazuharu Kamachi	Received

P-0479	TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K	Ton Falqués-Costa	Received

P-0481	FAILURE OF BONE MARROW ERYTHROPOIESIS IN ACUTE MYELOID LEUKEMIA IS DRIVEN BY LOSS OF ERYTHROBLASTIC ISLANDS	Delfim Duarte	Received

P-0484	GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 "MIDOTARG" PILOT TRIAL	Nigel Russell	Received

P-0485	AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY	Nicholas Short	Received

P-0486	REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED 60 AND =60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS	Priyanka Mehta	Received

P-0487	MIDOSTAURIN PLASMA EXPOSURE IN PATIENTS WITH FLT3-MUT ACUTE MYELOID LEUKEMIA UNDERGOING POSACONAZOLE PROPHYLAXIS DURING INDUCTION TREATMENT: A PROSPECTIVE MULTICENTRE STUDY FROM THE SEIFEM GROUP	Francesco Marchesi	Received

P-0488	SAFETY AND EFFICACY OF VENETOCLAX PLUS "7+3" CHEMOTHERAPY IN NEWLY DIAGNOSED AML	Ioannis Mantzaris	Received

P-0489	PROGNOSTIC IMPACT OF "MULTI-HIT" VERSUS "SINGLE-HIT" TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)	Talha Badar	Received

P-0490	UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE	Hartmut Döhner	Received

P-0491	DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDY	Agnieszka Wierzbowska	Received

P-0492	SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA	Kristin Koenig	Received

P-0493	ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC)	Harry Gill	Received

P-0494	A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA	Padmanabham Salla	Received

P-0495	UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE	Alfonso Piciocchi	Received

P-0497	CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION	Madlen Jentzsch	Received

P-0498	INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLASMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: THE PETHEMA-PALG EXPERIENCE.	Marta Sobas	Received

P-0502	PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (=60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT : MIDTERM UPDATE OF VEN-DEC GITMO STUDY	Domenico Russo	Received

P-505	GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA	Adriano Venditti	Received

P-0506	CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY	Panagiotis Baliakas	Received

P-0508	THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS	Lara Bischof	Received

P-0513	MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.	Gunnar Juliusson	Received

P-0516	CARDIOTOXICITY OF CPX-351 VS 73 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA	Joshua D. Mitchell	Received

P-0517	SURVIVAL OUTCOMES WITH CPX-351 VS 73 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY	Jorge Cortes	Received

P-0518	VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS	Yanyan Li	Received

P-0520	POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION	Ivetta Danylesko	Received

P-0521	FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)	Megan Ruzomberka	Received

P-0523	THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD	Alfonso Piciocchi	Received

P-0525	LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX HMA THERAPIES	Megan Ruzomberka	Received

P-0527	DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA	Hidemasa Matsuo	Received

P-0528	CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?	Jonas Schadt	Received

P-0529	THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA	Francesco Mannelli	Received

P-0530	CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION	Carola Riva	Received

P-0531	MIDOSTAURIN PLUS 7+3 OR QUIZARTINIB PLUS 7+3 IN FLT3-ITD MUTATED AML	Adolfo De La Fuente	Received

P-0532	KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.	Carlos Jimenez-Vicente	Received

P-0533	A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS	Christopher Maier	Received

P-0534	FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.	Pierre Peterlin	Received

P-0537	SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL	Janeen Nuttall	Received

P-0538	FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Maximilian Roehnert	Received

P-0539	A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS	Xiaojun Huang	Received

P-0540	RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)	Maria Amaya	Received

P-0541	REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)	Amer M. Zeidan	Received

P-0542	A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)	Mika Kontro	Received

P-0543	CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA	Rithin Nedumannil	Received

P-0544	SINGLE-SYSTEM UNIFOCAL ADULT LANGERHANS CELL HISTIOCYTOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY	Xin-Xin Cao	Received

P-0545	VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	Madelyn Burkart	Received

P-0547	UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING	Jacopo Nanni	Received

P-0548	PRELIMINARY RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY OF INA03, AN ANTI-CD71 ANTIBODY-DRUG CONJUGATE IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIAS	Sylvain Garciaz	Received

P-0550	INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML	Ivy Abraham	Received

P-0551	EVALUATION OF PROGNOSTIC FACTORS FOR SURVIVAL AND TREATMENT OUTCOMES OF PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA – A SINGLE-CENTER STUDY	Piotr Strzalka	Received

P-0552	MEASURABLE RESIDUAL DISEASE DETECTED BY WT1 IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHILDREN WITH ACUTE MYELOID LEUKEMIA	Mariam Elsherif	Received

P-0553	PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML	Paola Minetto	Received

P-0554	RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)	Katja Sockel	Received

P-0556	A NEW MULTIPLEX PCR TOOL ENABLES TIMELY IDENTIFICATION OF ACTIONABLE TARGETS FOR MOLECULAR-GUIDED THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Friedrich Stölzel	Received

P-0557	LIFETIME CLINICAL OUTCOMES OF CPX-351 VERSUS 73 MODELED FROM THE 5-YEAR RESULTS OF A RANDOMIZED PHASE 3 TRIAL FOR OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKAEMIA	Lin Fan	Received

P-0560	IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.	Yakir Moshe	Received

P-0562	CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT	Sari Kytölä	Received

P-0563	NOVEL GENES EXHIBITING FUNCTIONAL RELEVANCE IN KOREAN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM	Jiyeon Kim	Received

P-564	HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML	Xiao-Hua Luo	Received

P-0565	REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS	Sjoerd Hermans	Received

P-570	VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT	Zhangjie Chen	Received

P-0571	OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS	Roi Gat	Received

P-0572	REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE	Kristina Herberg	Received

P-0574	DIAGNOSIS AND TREATMENT OF T/MYELOID MIXED PHENOTYPE ACUTE LEUKAEMIA (T/M-MPAL)- A UK SINGLE CENTRE EXPERIENCE	Enas Abusalim	Received

P-0575	GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

P-0576	PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS - A SINGLE-CENTER EXPERIENCE	Victor Ling	Received

P-581	A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA	Mithunan Ravindran	Received

P-0590	MODIFICATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UKRAINIAN PROSPECTIVE STUDY IN A REAL-LIFE COHORT.	Zinaida Stupakova	Received

P-0593	T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA	Eric Eldering	Received

P-0594	THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL	Federico Pozzo	Received

P-0595	DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	Helga Simon-Molas	Received

P-0597	XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING	Donatella Talotta	Received

P-0601	GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS	Pieter Martijn Kolijn	Received

P-0604	CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE SENSITIVE TO THE APOLIPOPROTEIN E-MEDIATED DISRUPTION OF METABOLIC HOMEOSTASIS	Federica Nardi	Received

P-0605	IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4	Anastasia Iatrou	Received

P-0606	MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL	Filippo Vit	Received

P-0608	THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.	Lluís Hernández	Received

P-0609	EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.	Maria Andersson	Received

P-0612	ASSESSMENT OF THE DEVELOPMENT OF B CELL MALIGNANCIES IN A NOVEL MURINE MODEL CARRYING DLEU2 DELETION	Alice Ramassone	Received

P-0616	LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL	Emily Liang	Received

P-0617	FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY	Paolo Ghia	Received

P-0618	LONG-TERM SAFETY WITH =12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES	Wojciech Jurczak	Received

P-619	TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.	Sabina Kersting	Received

P-0621	REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT	Michelle Parrish	Received

P-0623	MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR	Othman Al-Sawaf	Received

P-0627	LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION	Michelle Parrish	Received

P-0628	UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES	Farrukh Awan	Received

P-0629	THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL	Carsten Niemann	Received

P-0632	COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS	Steven Hwang	Received

P-0634	EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA	Paul Hengeveld	Received

P-0637	TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL	Jan Burger	Received

P-0641	REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA	Anna Teschemaker	Received

P-0644	IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS	Jan Burger	Received

P-0645	IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS	Michelle Parrish	Received

P-0647	RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL	Joanna M. Rhodes	Received

P-0648	REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY	Beth Stapleton	Received

P-0652	IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.	Tamar Tadmor	Received

P-0654	ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY	Hiroshi Ureshino	Received

P-0658	DEVELOPMENT OF THE HIGHLY ACCURATE AND SENSITIVE METHOD USING THE CHIP-BASED DIGITAL PCR (LOAA) FOR THE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING WHOLE PERIOD OF CHRONIC MYELOID LEUKEMIA TREATMENT	Hyun-Woo Song	Received

P-0661	EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS	Seiichi Okabe	Received

P-0664	REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS	Shiwei Hu	Received

P-0667	RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY	Carlo Gambacorti-Passerini	Received

P-0672	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES	Fadi Haddad	Received

P-0675	IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY	Lucy Pemberton	Received

P-0679	SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES	Georg-Nikolaus Franke	Received

P-0681	MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA	Teresa Kangappaden	Received

P-0684	A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS	Jian Huang	Received

P-0687	EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA	Aram Bidikian	Received

P-0688	ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)	Ehab Atallah	Received

P-0689	CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?	Claudia Haferlach	Received

P-0690	IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172	Maki Sakuma	Received

P-0691	MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS	Yu-Hung Wang	Received

P-0694	RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?	Gregor Hoermann	Received

P-0698	CRISPR/CAS9 GENE EDITING IN HEMATOPOIETIC STEM CELLS TO MODEL CLONAL COMPETITION IN VIVO AND IN VITRO FOR GATA2 DEFICIENCY	Damia Romero-Moya	Received

P-0699	MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)	Kelly Taylor	Received

P-0701	SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS	Athanasios Tasis	Received

P-0703	THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS	Adrian Mosquera-Orgueira	Received

P-0705	AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX	Amanpreet Bains	Received

P-0706	RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME	Ioannis Kotsianidis	Received

P-0708	HIGH MUTATIONAL CONCORDANCE IN PAIRED BONE MARROW AND PERIPHERAL BLOOD SAMPLES IN PATIENTS WITH CONFIRMED OR SUSPECTED MYELODYSPLASTIC NEOPLASM	Natalie Wossidlo	Received

P-0709	H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA	Moritz Binder	Received

P-0710	MONOCYTES MEDIATE NK CELL FUNCTION EXHAUSTION IN MDS PATIENTS VIA CD200/CD200R PATHWAY	Yixuan Guo	Received

P-0712	SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME	Xingcheng Yang	Received

P-713	EXPLORING CLONAL COMPETITION THROUGH 12-YEAR FOLLOW-UP OF AN MDS-RS PATIENT WITH DUAL SF3B1 MUTATIONS	Pedro Moura	Received

P-0714	DISSECTING THE CLINICAL HETEROGENEITY OF ISOLATED TRISOMY 8 MYELODYSPLASTIC SYNDROMES THROUGH MUTATIONAL PROFILE	Sofía María Toribio Castelló	Received

P-0715	TOX REGULATED CD8+ T LYMPHOCYTES EXHAUSTED IN MYELODYSPLASTIC SYNDROMES PATIENTS THROUGH ACTIVATING AKT/PI3K/MTOR PATHWAY	Huaquan Wang	Received

P-0716	GENE EXPRESSION ANALYSIS REVEALS UNIQUE CHARACTERISTICS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS	Wanshu Chen	Received

P-0717	AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Jonathan De Wilde	Received

P-0718	EPIGENOME PROFILING REVEALS ABERRANT DNA METHYLATION SIGNATURE IN GATA2 DEFICIENCY	Damia Romero-Moya	Received

P-0720	A BONE MARROW MICROENVIRONMENTAL CELL SIGNATURE SCORING SYSTEM INDEPENDENTLY PREDICTED SURVIVAL AND DRUG RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS	Yu-Hung Wang	Received

P-0721	VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION	Wan Hsuan Lee	Received

P-0724	UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME	Courtney Dinardo	Received

P-0725	BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY	Felicitas Schulz	Received

P-0726	TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA	Yu-Hung Wang	Received

P-0727	REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS	Luis E. Aguirre	Received

P-0728	EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS	Samuel Urrutia	Received

P-0737	LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL	David Ross	Received

P-0742	THE VALUE OF S100A8 AND S100A9 FOR DIAGNOSIS AND PROGNOSTIC PREDICTION IN MYELODYSPLASTIC NEOPLASMS	Yu Wu	Received

P-0743	CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS	Samuel Urrutia	Received

P-0745	MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS	Jan Bewersdorf	Received

P-0746	REAL-WORLD ANALYSIS OF A LARGE ELECTRONIC MEDICAL RECORD DATABASE OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): TREATMENT PROFILES, CLINICAL EFFECTIVENESS, AND KEY ADVERSE EVENTS	Kelly Taylor	Received

P-0748	IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE	Samuel Urrutia	Received

P-0749	THE ROLE OF INCREASED IRF1 EXPRESSION OF NATURAL KILLER CELLS IN THE IMMUNE PATHOGENESIS OF SEVERE APLASTIC ANAEMIA	Liu Zixuan	Received

P-0750	A ZEBRAFISH MODEL FOR JAGN1-ASSOCIATED SEVERE CONGENITAL NEUTROPENIA	Larissa Doll	Received

P-0752	TRANSCRIPTOMIC ANALYSIS OF MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA (CIN)	Nikoleta Bizymi	Received

P-0755	STUDIES OF THE SPECIFIC TCIRG1 MUTATIONS CAUSING CONGENITAL NEUTROPENIA	Vahagn Makaryan	Received

P-0756	IMPAIRED MITOCHONDRIAL FUNCTION AND MARROW FAILURE IN PATIENTS CARRYING A MUTATION ON SRSF4 GENE	Maurizio Miano	Received

P-0757	INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Jesse Fishman	Received

P-0759	LANDSCAPE OF BONE MARROW T CELLS IN ACQUIRED APLASTIC ANAEMIA REVEALS AN ACTIVATED STATE AND A POTENTIAL CLONAL EXPANSION	Yan Liu	Received

P-0760	EXOSOMES FROM GRANULOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS ALLEVIATE MURINE IMMUNE-MEDIATED BONE MARROW FAILURE	Ash Lee Manley	Received

P-0762	HEMATOPOIETIC PROGENITOR CELL-REACTIVE T CELL CLONES CAN RECOGNIZE VIRAL EPITOPES IN APLASTIC ANEMIA BONE MARROW	Amin Ben Hamza	Received

P-0763	EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA	Ting Zhang	Received

P-0764	DIFFERENTAL ERYTHROPOIESIS IN BONE MARROW OF PNH PATIENTS WERE REVEALED BY SINGLE-CELL SEQUENCING	Hui Liu	Received

P-0765	MIB2/SUZ12 REGULATED THE PROLIFERATION OF PNH CLONE	Lijie Zeng	Received

P-0766	ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS	Zenghua Lin	Received

P-768	PRELIMINARY EXPLORATION ON LAG-3 EXPRESSION OF BONE MARROW-DERIVED MACROPHAGES IN SEVERE APLASTIC ANEMIA	Congwei Zhong	Received

P-0770	IDENTIFYING GENES ASSOCIATED WITH PROLIFERATION AND THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Yali Du	Received

P-0773	CYCLOPHOSPHAMIDE COMBINED WITH PREDNISONE FOR CYCLOSPORINE-REFRACTORY/RELAPSED T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA ASSOCIATED PURE RED CELL APLASIA	Xiaoqing Liu	Received

P-0775	LONG-TERM EFFICACY AND SAFETY OF POZELIMAB MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Morag Griffin	Received

P-0777	EFFICACY AND SAFETY OF ROMIPLOSTIM COMBINED WITH CYCLOSPORINE A AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL.	Shigeru Chiba	Received

P-778	A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS ITALIAN EXPERIENCE	Carmelo Gurnari	Received

P-0782	A PHASE 2, RANDOMIZED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Jun-Ho Jang	Received

P-0790	DISTINCT MUTATIONAL PATTERN OF T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA COMBINED WITH PURE RED CELL APLASIA: LOW MUTATIONAL BURDEN OF STAT3	Sooyong Park	Received

P-0792	CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA	Lixian Chang	Received

P-0793	EFFICACY AND IN VIVO EFFECTS OF PORCINE ANTIHUMAN LYMPHOCYTE IMMUNOGLOBULIN COMPARED TO RABBIT ANTITHYMOCYTE IMMUNOGLOBULIN IN SEVERE APLASTIC ANEMIA	Yu Sun	Received

P-0795	NEUTROPENIA IN CHILDHOOD IS MOST FREQUENTLY DUE TO AN AUTOIMMUNE PROCESS AND HAS A BENIGN COURSE.	Konstantina Toutoudaki	Received

P-0797	A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB	Richard Kelly	Received

P-0798	DIAMOND BLACKFAN ANEMIA MAY ESCAPE DIAGNOSIS UP TO ADULTHOOD; A REPORT FROM THE UPDATED GREEK REGISTRY	Polyxeni Delaporta	Received

P-0800	CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA	Sojeong Kim	Received

P-0807	CLASS ? FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA	Chunyan Sun	Received

P-0811	PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA	Zhaoyun Liu	Received

P-0813	MALIGNANT PLASMA CELLS PROMOTE EXPANSION OF REGULATORY T CELLS TO CREATE A PROTECTIVE "IMMUNE SHIELD"	Roberto Limongello	Received

P-0814	ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA	Marietta Truger	Received

P-0817	VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Christian Brieghel	Received

P-819	CONTRIBUTION OF IMMUNOPHENOTYPING OF BONE MARROW B CELLS AND PLASMA CELLS IN THE DIAGNOSTIC CLASSIFICATION OF INDIVIDUALS PRESENTING WITH A SERUM M-PROTEIN	Juan Flores-Montero	Received

P-0820	POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA	Shinya Hagiwara	Received

P-0822	EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES	Laura Martinez-Verbo	Received

P-0823	BONE MARROW-FREE SEQUENCING OF M PROTEIN GENES IN MONOCLONAL GAMMOPATHIES	Mario Nuvolone	Received

P-0826	THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING	Maria Papatsirou	Received

P-0827	STUDY ON THE PERCENTAGE AND FUNCTION OF TSCM CELLS AND THE ANTITUMOR EFFECT IN VITRO AMPLIFICATION IN PATIENTS WITH MULTIPLE MYELOMA	Panpan Cao	Received

P-0829	GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA	Anke Schilhabel	Received

P-0830	IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA	Nicolas Thomas Iannozzi	Received

P-0831	NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS	Jens Hillengass	Received

P-0832	PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T(11;14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY	Maria Gavriatopoulou	Received

P-0833	MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA	Hamed Bashiri	Received

P-0834	MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES	Tina Bagratuni	Received

P-0835	IN SILICO PREDICTION REVEALS PUTATIVE T-CELL CLASS I/II NEOEPITOPES WITHIN THE CLONOTYPIC IMMUNOGLOBULIN HEAVY AND LIGHT CHAINS IN PATIENTS WITH MULTIPLE MYELOMA	Glykeria Gkoliou	Received

P-0840	ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL.	Natalia Buenache Cuenda	Received

P-0841	MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY	Raquel Alves	Received

P-0847	BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.	Valentina Traini	Received

P-0848	EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.	Cristina De Ramón Sánchez	Received

P-0850	THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA	Alba Rodríguez-García	Received

P-851	ANTIBODY TARGETING OF SOLUBLE MHC-CLASS-I-RELATED MOLECULE AUGMENTS NATURAL KILLER CELL FUNCTION BY RESTORING NKG2D IN MULTIPLE MYELOMA	Hyunsoo Cho	Received

P-0852	ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS	Grazia Scandura	Received

P-0853	AUTOMATED SEPARATION OF CELL CLUSTERS PROVIDES AN EASY AND ACCURATE STRATEGY FOR THE ANALYSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MIELOMA IN SINGLE 11-COLORS FLOW CYTOMETRY COMBINATION.	Paula Piñero	Received

P-0855	FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA	Alessandra Romano	Received

P-0856	MULTIPLE MYELOMA DERIVED IL-6 REDUCES FATTY ACID METABOLISM IN THE LIVER BY DOWNREGULATING CD36 AND CPT1A IN HEPATOCYTES	Martha Egheose Ehikioya	Received

P-0857	COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN 2022 ACROSS UNITED STATES, SOUTH AMERICA, EUROPE AND ASIA	Philippe Capart	Received

P-0859	PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA	Christian Brieghel	Received

P-0860	CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS	Ilaria Vigliotta	Received

P-0861	PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY	Panagiotis Malandrakis	Received

P-0863	AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Emma Searle	Received

P-0869	UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Juan Du	Received

P-0872	EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)	Meral Beksac	Received

P-0875	REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY	Frida Bugge Askeland	Received

P-0876	ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS	Enrique Maria Ocio San Miguel	Received

P-0877	IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY	Kaz Groen	Received

P-0878	SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY	Paula Rodríguez-Otero	Received

P-0884	BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY	Evangelos Terpos	Received

P-885	SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES	Charalampos Charalampous	Received

P-0887	PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	Luis-Esteban Tamariz-Amador	Received

P-0889	POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA	Hila Magen	Received

P-0890	COMBINING SKY92 GENE EXPRESSION PROFILING WITH CYTOGENETICS ACCORDING TO R2-ISS FOR MULTIPLE MYELOMA RISK CLASSIFICATION: THE FIRST PROSPECTIVE EVIDENCE	Xiang Zhou	Received

P-0891	IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).	Margaret Macro	Received

P-0894	INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY	Marina Ros Levy	Received

P-0895	DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL	Vittorio Montefusco	Received

P-0896	VALUE OF 18F-FDG PET/CT IN THE EVALUATION OF ORGAN INVOLVEMENT IN NEWLY DIAGNOSED PRIMARY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS	Junru Liu	Received

P-0897	EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.	Eirini Katodritou	Received

P-0898	A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS	Raija Silvennoinen	Received

P-0899	HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS	Monique Minnema	Received

P-0900	INVOLVED/UNINVOLVED SERUM FREE LIGHT CHAIN RATIO IS A STRONGER PREDICTOR OF DIAGNOSTIC/RISK FACTORS IN LIGHT CHAIN COMPARED TO HEAVY CHAIN MONOCLONAL GAMMOPATHIES	Jon Thorir Oskarsson	Received

P-0901	DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY	Evangelos Terpos	Received

P-0903	CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY	Mackenzie Maberry	Received

P-0910	DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS	Jahanzaib Khwaja	Received

P-0912	ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION	Sonia More´	Received

P-0914	VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY	Iuliana Vaxman	Received

P-0916	LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY	Himanshi Bhatia	Received

P-0918	ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL	Claudio Cerchione	Received

P-0920	EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.	Eirini Katodritou	Received

P-0925	PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA	Wenming Chen	Received

P-0926	ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA	Juan Du	Received

P-0927	ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.	Nicolas Blin	Received

P-0928	OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL	Evangelos Terpos	Received

P-0932	PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP	Jay R. Hydren	Received

P-0934	THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Yi Tao	Received

P-0937	CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.	Antonio Garcia-Guiñon	Received

P-0938	SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES	Hakima Mechiche	Received

P-0941	SERUM CXCL13 LEVEL AIDS IN DISEASE REMISSION EVALUATION AND PROGNOSIS PREDICTION IN WALDENSTRÖM MACROGLOBULINEMIA	Jia Chen	Received

P-0942	MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY	Yael Cohen	Received

P-0944	REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK	Ivan Spicka	Received

P-0947	TREATMENT PATTERNS AND OUTCOMES OF RE-INDUCTION THERAPIES PRIOR TO STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED IN CLINICAL PRACTICE IN GERMANY	Sandra Sauer	Received

P-948	REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA	Maria Nieves Lopez Muñoz	Received

P-0950	PRIOR CANCER AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): A POPULATION-BASED STUDY IN ICELAND AND SWEDEN	Sæmundur Rögnvaldsson	Received

P-0951	IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)	Bruno Paiva	Received

P-952	PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER	Xuelin Dou	Received

P-0953	ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL	Claudio Cerchione	Received

P-0954	MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY	Vania Hungria	Received

P-0956	VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)	Efstathios Kastritis	Received

P-0960	EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.	Annamaria Brioli	Received

P-0961	BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS	Thomas Hueso	Received

P-0962	COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.	Ross Firestone	Received

P-0963	EXTRAMEDULLARY MULTIPLE MYELOMA: CLINICAL CHARACTERISTICS, IMPACT, AND OUTCOMES IN A COHORT OF PATIENTS IN MEXICO	Amaya Llorente Chávez	Received

P-0966	SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM	Yael Cohen	Received

P-0967	A MACHINE LEARNING MODEL FOR RISK PREDICTION IN MULTIPLE MYELOMA PROGRESSING AFTER THE FIRST LINE OF THERAPY	Adrian Mosquera-Orgueira	Received

P-0969	VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY	Jakob Nordberg Nørgaard	Received

P-0971	EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.	Francesca Fazio	Received

P-0973	ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE	Sonia More´	Received

P-0976	REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS	Jun Ho Yi	Received

P-0977	THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA	Tugcan Alp Kirkizlar	Received

P-0978	EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS	Firas Al-Kaisi	Received

P-0980	THE ROLE OF PLATELET AND ENDOTHELIAL MICROPARTICLES AND DOPPLER ULTRASOUND SCREENING IN THE ASSESSMENT OF THROMBOTIC READINESS IN MULTIPLE MYELOMA AND NON HODGKIN LYMPHOMA, PROSPECTIVE STUDY	Magdalena Olszewska-Szopa	Received

P-0981	DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES OF MYELOMA PATIENTS <50 YEARS OF AGE: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP	Efstathios Kastritis	Received

P-984	DIFFERENTIAL IMPACTS OF DISTINCT MUTATION SUBTYPES ON ALTERED S100A8 EXPRESSION AND PHENOTYPIC HETEROGENEITY IN CALR-MUTANT MPN	Chih-Cheng Chen	Received

P-0985	CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA	Juwita Huebner	Received

P-0986	COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS	Zachary Zaroogian	Received

P-0987	IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL	Ernesto José Cuenca Zamora	Received

P-0988	MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS	Kristin Holl	Received

P-0990	NF-?B AND JAK/STAT PATHWAYS INHIBITION REVERSES FIBROSIS IN A MURINE MODEL OF INFLAMMATION-DRIVEN MYELOFIBROSIS	Ernesto José Cuenca Zamora	Received

P-0993	INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS	Marie Ploderer	Received

P-0994	GERMLINE SINGLE-NUCLEOTIDE VARIANTS (SNV) IN THE JAK-STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)	Alice Diepers	Received

P-0995	INDEED: A DEEP LEARNING MODEL FOR DIAGNOSIS AND SUBTYPES DIFFERENTIATION OF MYELOPROLIFERATIVE NEOPLASM BASED ON INTELLIGENCE NEURAL NETWORK	Rong Wang	Received

P-0996	A NOVEL GERMLINE GAIN-OF-FUNCTION JAK2 MUTATION: L604F	Lukas Dvoracek	Received

P-0999	ROLE OF GENETIC VARIANTS IN PREDICTING EFFICACY AND/OR ADVERSE EVENTS OF ROPEGINTERFERON ALPHA-2B IN MPN PATIENTS: A RETROSPECTIVE ANALYSIS FROM AN ASIAN COHORT	Chih-Cheng Chen	Received

P-1001	MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES	Velizar Shivarov	Received

P-1003	RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.	Ciro Rinaldi	Received

P-1007	SPLENOMEGALY DEVELOPMENT PRECEDES THE PROGRESS OF HEMATOPOIETIC STEM CELLS MIGRATION TO SPLEEN IN MURINE MYELOFIBROSIS MODELS	Takaaki Maekawa	Received

P-1009	SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION	Ailin Zhao	Received

P-1010	PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS HAVE INCREASED NUMBERS OF MYELOID-DERIVED SUPPRESSOR CELLS, AND DECITABINE MAY HAVE A SIGNIFICANT THERAPEUTIC EFFECT IN MPN PATIENTS WITH HIGH MDSCS	Jian Huang	Received

P-1011	NOVEL 12-COLOR FCM + NGS STRATEGY FOR THE ACCURATE DIAGNOSIS AND STRATIFICATION OF CHRONIC MYELOMONOCYTIC LEUKEMIA. EXPERIENCE FROM THE HEMATOLOGICAL DIAGNOSIS GROUP OF ALICANTE.	Paula Piñero	Received

P-1012	CHARACTERIZING JAK2 MUTATED AND UNMUTATED ERYTHROCYTOSIS: A CLINICAL AND GENETIC COMPARISON	Sang Mee Hwang	Received

P-1013	CBL MUTATION MAY BE ASSOCIATED WITH THE ONSET OF MYELOPROLIFERATIVE NEOPLASMS WITH MICROVASCULAR DISORDERS: A SINGLE-CENTRE EXPERIENCE	Giorgia Micucci	Received

P-1016	RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS	Andrew Kuykendall	Received

P-1022	PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS	Prithviraj Bose	Received

P-1025	A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.	Prithviraj Bose	Received

P-1028	MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)	Francesca Palandri	Received

P-1030	SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS	Jan Bewersdorf	Received

P-1032	CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL	Ruben Mesa	Received

P-1036	REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS	Johannes Lübke	Received

P-1037	CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS	Nico Gagelmann	Received

P-1039	LOW DOSE CYTARABINE FOR ADULT PATIENTS WITH NEWLY DIAGNOSED LANGERHANS CELL HISTIOCYTOSIS: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY	Long Chang	Received

P-1040	FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS	Gopila Gupta	Received

P-1041	LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT	Tiziano Barbui	Received

P-1045	DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST	Rami S. Komrokji	Received

P-1046	TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS	Michael Grunwald	Received

P-1047	AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB	Andrea Duminuco	Received

P-1048	PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES	Marina Kremyanskaya	Received

P-1051	CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS	Ivan Krecak	Received

P-1053	NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Mirjana Cvetkovic	Received

P-1054	CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING	Marta Garrote Ordeig	Received

P-1055	BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY	Justin M. Watts	Received

P-1056	NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES	Valentina Sangiorgio	Received

P-1058	CHILDHOOD-ONSET ERDHEIM-CHESTER DISEASE IN THE MOLECULAR ERA: CLINICAL PHENOTYPE AND LONG-TERM OUTCOME OF 21 PATIENTS	Francesco Pegoraro	Received

P-1060	THE IMPACT OF POLYCYTHEMIA VERA ON DAILY LIVING, AND SYMPTOM AND TREATMENT PERCEPTION GAPS BETWEEN PATIENTS AND PHYSICIANS: RESULTS OF A CROSS-SECTIONAL SURVEY IN JAPAN	Yuka Sugimoto	Received

P-1061	CLINICAL FEATURES OF PHILADELPHIA-NEGATIVE MPN DEVELOPED IN ADOLESCENTS AND YOUNG ADULTS IN JAPAN	Yuka Sugimoto	Received

P-1069	GONADAL FUNCTION AND FERTILITY PRESERVATION IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA TREATED ACCORDING TO THE EURONET-PHL-C2 PROTOCOL: THE FERTILITY ADD-ON STUDY	Katja Drechsel	Received

P-1070	DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE	Paolo Corradini	Received

P-1074	PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA	Wenyan Yu	Received

P-1075	ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS	Alessandro Cellini	Received

P-1076	PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS	Eldad Dann	Received

P-1077	RISK OF IMPAIRED OVARIAN RESERVE AND ADVERSE PREGNANCY OUTCOMES AFTER TREATMENT FOR CHILDHOOD HODGKIN LYMPHOMA; THE DCOG LATER-VEVO STUDY.	Katja Drechsel	Received

P-1079	VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.	Clementine Sarkozy	Received

P-1081	A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE	Annalisa Chiappella	Received

P-1083	ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2	Michal Taszner	Received

P-1085	HISTOLOGICAL TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 48 MONTHS (TOD48) INDICATING AN ADVERSE PROGNOSIS: EVIDENCE FROM TWO POPULATION-BASED COHORTS	Hong-Hui Huang	Received

P-1086	EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN´S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE	Yukihiro Nishio	Received

P-1087	PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT	Wojciech Jurczak	Received

P-1088	COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS	Declan O´Dea	Received

P-1089	ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA	Chang-Ju Qu	Received

P-1090	LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.	Benoit Tessoulin	Received

P-1091	CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA	Rosalia Malafronte	Received

P-1092	A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA	Paolo Strati	Received

P-1094	SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL	Tycel Phillips	Received

P-1097	CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY	Mazyar Shadman	Received

P-1098	A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)	Janeen Nuttall	Received

P-1101	A PROSPECTIVE TRIAL OF A NOVEL RECOMBINANT HUMANIZEDANTI-INTERLEUKIN-6 RECEPTOR MONOCLONAL ANTIBODY INJECTION(VDJ001) IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: THE PRELIMINARY RESULTS	Lu Zhang	Received

P-1102	IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY	Rohan Shotton	Received

P-1103	OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA	Tomasz Wróbel	Received

P-1106	CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.	Kei Hirano	Received

P-1108	EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY	Lydia Scarfò	Received

P-1109	EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.	Erika Morsia	Received

P-1111	WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (=75-YEAR-OLD): DESCRIPTION OF CLINICAL FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN ACADEMIC CENTER	Nicolò Danesin	Received

P-1112	PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY	Nalin Payakachat	Received

P-1115	ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2	Jan Walewski	Received

P-1120	NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.	Shen Yige	Received

P-1122	A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA	Stefan Habringer	Received

P-1125	DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)	Javier Munoz	Received

P-1127	FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL	Emma Verner	Received

P-1128	EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY	Elise R.A. Pennings	Received

P-1131	SERUM TRIGLYCERIDE AND APOLIPOPROTEIN A1 AS BIOMARKERS FOR EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (ENKTL): A MULTICENTER STUDY	Qingqing Cai	Received

P-1137	COMBINED METABOLIC HETEROGENEITY AND TOTAL LESION GLYCOLYSIS FROM PET-CT IMPROVES THE PROGNOSTIC STRATIFICATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA	Daisuke Ikeda	Received

P-1139	COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS	Carolien Maas	Received

P-1143	ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Bobin Chen	Received

P-1144	PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Alexander Fossa	Received

P-1146	TRANSFUSION NEEDS AFTER CD19 CAR T-CELLS FOR LARGE B-CELL LYMPHOMA: PREDICTIVE FACTORS AND IMPACT ON OUTCOME. A DESCAR-T STUDY.	Samuel Vic	Received

P-1147	FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL	Josep Maria Ribera	Received

P-1148	MULTI-SITE PRE-THERAPEUTIC BIOPSIES REVEALS GENETIC HETEROGENEITY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA	Ditte Stampe Hersby	Received

P-1151	BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	Gloria Ines Iacoboni Garcia-Calvo	Received

P-1152	DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Allison Bock	Received

P-1156	IN THE ABSENCE OF SYMPTOMS OR CEREBROSPINAL FLUID INVOLVEMENT, MRI STAGING OF THE CENTRAL NERVOUS SYSTEM (CNS) IN PATIENTS WITH SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA RARELY DETECTS DISEASE	Manu Juneja	Received

P-1158	REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT OUTCOMES OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) BY LINE OF THERAPY (LOT)	Christina Zettler	Received

P-1159	INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP	Diana Al-Sarayfi	Received

P-1161	THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.	Francien Huisman	Received

P-1163	ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA	Ling Wang	Received

P-1166	BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN	David Sibon	Received

P-1167	TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB),A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION	Yiyou Chen	Received

P-1171	CNS RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL PRESENTATION, OUTCOME AND ROLE OF UPFRONT PROPHYLAXIS: A 10-YEAR SINGLE CENTER EXPERIENCE.	Corrado Benevolo Savelli	Received

P-1172	ARTIFICIAL INTELLIGENCE FOR PROGNOSIS PREDICTION OF NATURAL KILLER/T-CELL LYMPHOMA BASED ON MAGNETIC RESONANCE IMAGING	Qingqing Cai	Received

P-1174	PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY	Zhi-Ming Li	Received

P-1175	THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES	Ivan Civettini	Received

P-1180	BURKITT INTERNATIONAL PROGNOSTIC INDEX EVALUATED IN PATIENTS TREATED WITH R-GMALL PROTOCOL	Giuliana Rizzuto	Received

P-1181	REAL-LIFE TREATMENT APPROACHES AND THERAPY RESULTS IN THE PATIENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA: POLISH-UKRAINIAN EXPERIENCE	Kateryna Filonenko	Received

P-1184	INTERIM DELTASUVMAX CAN IDENTIFY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA WITH A HIGH RISK OF PRIMARY REFRACTORY DISEASE CANDIDATES FOR EARLY CART COLLECTION	Carolina Feres	Received

P-1189	ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY	Ronakrit Thanhakun	Received

P-1192	ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPENTIVE PHASE II STUDY	Wen Shujuan	Received

P-1193	POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY	Briony Shaw	Received

P-1194	PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS	Deok Hwan Yang	Received

P-1196	ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL	Chang-Ju Qu	Received

P-1197	BRUTON´S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM: A PHASE II TRIAL	Yali Wang	Received

P-1198	A POPULATION-BASED STUDY REVEALS THE UNIQUE CLINICAL CHARACTERISTICS AND LONG-TERM SURVIVAL OF PATIENTS WITH GRAY ZONE LYMPHOMA	Xin Wang	Received

P-1200	ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY	Stephen Spurgeon	Received

P-1201	A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA	Xin Wang	Received

P-1202	NOVEL METHODS FOR THE IDENTIFICATION OF A RARE DISEASE, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)	Catherine M Broome	Received

P-1203	EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION	Li Wang	Received

P-1205	A LIVING PATIENT-DERIVED BIOREPOSITORY FOSTERING MICROENVIRONMENT DISSECTION IN T-CELL LYMPHOMA	Danilo Fiore	Received

P-1207	SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY	Lydie Debaize	Received

P-1208	TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA	Robel Papotti	Received

P-1210	TARGETING PTGDS AS A NOVEL THERAPEUTIC APPROACH IN PERIPHERAL T CELL LYMPHOMA THROUGH REGULATING IRON METABOLISM	Shunfeng Hu	Received

P-1211	TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA	Alan Ramsay	Received

P-1212	RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA	Danielle H. Oh	Received

P-1213	ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA	Martha-Lena Müller	Received

P-1215	CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA	Zhi-Zhang Yang	Received

P-1217	TARGETING HSP110 IN COMBINATION WITH SELINEXOR IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND IN CLASSICAL HODGKIN LYMPHOMA INHIBITS STAT6 ACTIVATION AND IMPAIRS LYMPHOMA CELL GROWTH	Manon Durand	Received

P-1222	ANTIGEN-INDEPENDENT, CELL-AUTONOMOUS SIGNALING IN SPLENIC MARGINAL ZONE LYMPHOMA	Anastasia Iatrou	Received

P-1224	PATIENT-DERIVED XENOGRAFT (PDX) IS A USEFUL TOOL FOR EVALUATING 5-AZACYTIDINE SENSITIVITY IN TFH LYMPHOMAS	Gamze Tari	Received

P-1225	CYLD, A NOVEL REGULATOR OF SPLENIC MARGINAL ZONE LYMPHOMA PATHOGENESIS	Athanasios Pseftogkas	Received

P-1226	BTG2, A NOVEL TARGET OF MIR-17-92, REGULATES B CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA	Yuka Kawaji-Kanayama	Received

P-1228	GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES	Sanna Timonen	Received

P-1230	T CELL CD62L EXPRESSION FOLLOWING NIVOLUMAB THERAPY IS ASSOCIATED WITH LONG TERM RESPONSE TO RITUXIMAB-NIVOLUMAB IN TREATMENT NAÏVE FOLLICULAR LYMPHOMA: RESULTS FROM THE 1ST FLOR STUDY	Rachel Koldej	Received

P-1231	IMPACT OF ARID1A AND TP53 MUTATIONS IN PEDIATRIC REFRACTORY OR RELAPSED MATURE B-CELL LYMPHOMA TREATED WITH CAR-T CELL THERAPY	Qinlong Zheng	Received

P-1232	NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Roberta Soscia	Received

P-1234	A PROGNOSTIC MODEL BASED ON GENE EXPRESSION PARAMETERS PREDICTS A BETTER RESPONSE TO BORTEZOMIB-CONTAINING IMMUNOCHEMOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA	Adrian Mosquera-Orgueira	Received

P-1235	INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL	Matteo Villa	Received

P-1237	HSF1 PROMOTES CHEMORESISTANCE IN DIFFUSE LARGE B-CELL LYMPHOMA VIA A PRMT5-DEPENDENT TRANSCRIPTIONAL PROGRAM HSF1??PRMT5?????????????B???????????	Qingqing Cai	Received

P-1238	GERMLINE HAVCR2 MUTATIONS AND THEIR RELATION TO THE CLINICAL SPECTRUM OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA AND HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: RESULTS FROM A MULTICENTER STUDY	Chantana Polprasert	Received

P-1240	MICROBIOME DIVERSITY IN PATIENTS WITH LYMPHOMA	Lucie Dlouha	Received

P-1245	PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA	Bence Bátai	Received

P-1249	INSUFFICIENT PPAR? IN BONE MARROW ENDOTHELIAL PROGENITOR CELLS LEADS TO THEIR IMPAIRED HEMATOPOIESIS-SUPPORTING ABILITY	Mi Liang	Received

P-1253	REDUCED EXPRESSION OF THE CHEMOKINES CXCL2, CXCL3 AND CXCL8 PROVIDES A POTENTIAL MECHANISM PROMOTING IMMUNE EVASION FACILITATING AML RELAPSE FOLLOWING ALLOGENEIC HSCT	Sarah Charrot	Received

P-1254	BASELINE HLA-DR-RESTRICTED NEOANTIGEN BURDEN OF AML BLASTS IMPACTS ON HLA-DR GENE EXPRESSION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT	Sarah Charrot	Received

P-1256	IMPACT OF CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON HEMATOPOIETIC RECONSTITUTION: A SINGLE-CENTER EXPERIENCE.	Esther Ortega Vida	Received

P-1261	NEGATIVE IMPACT OF HLA-B LEADER MISMATCH ON OUTCOMES OF HCT WITH PTCY FOR LYMPHOID MALIGNANCIES: A RETROSPECTIVE ANALYSIS FROM THE JAPANESE SOCIETY FOR TRANSPLANTATION AND CELLULAR THERAPY	Minoru Kanaya	Received

P-1262	GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION	Chen Liang	Received

P-1263	SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ENDOTHELIAL DAMAGE AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Lilli Leimi	Received

P-1264	A PREDEFINED STRATEGY AIMED TO REDUCE ANTIBIOTIC EXPOSURE OF SCT RECIPIENTS PRESERVES DIVERSITY AND COMPOSITION OF INTESTINAL MICROBIOTA AND REDUCES THE INCIDENCE OF ACUTE-GVHD WITHOUT SIDE EFFECTS	Ildefonso Espigado	Received

P-1265	UNRELATED FEMALE-TO-MALE BONE MARROW TRANSPLANTATION SHOULD BE PREFERRED OVER CORD BLOOD TRANSPLANTATION IN MALE RECIPIENTS.	Masaharu Tamaki	Received

P-1266	THE SKIRT CALCULATOR DYNAMICALLY TRACKS IMMUNE RECONSTITUTION AND PREDICTS CLINICAL OUTCOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yigeng Cao	Received

P-1268	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK MYELODYSPLASTIC NEOPLASMS: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS	Jan Christian Schröder	Received

P-1269	PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE	Jonaphine Mata	Received

P-1270	MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES	Uday R. Popat	Received

P-1272	DEFIBROTIDE IMPACT ON THE ACUTE GRAFT-VERSUS-HOST DISEASE INCIDENCE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.	Daniela Nistico´	Received

P-1274	IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS	Liat Shargian	Received

P-1277	IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML	Jian-Ying Zhou	Received

P-1279	OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES	Oren Pasvolsky	Received

P-1282	MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Michael Medinger	Received

P-1286	MIXED CHIMAERISM IS ASSOCIATED WITH POORER LONG-TERM FAILURE-FREE SURVIVAL AMONG APLASTIC ANAEMIA PATIENTS RECEIVING HLA-MATCHED DONOR TRANSPLANTATION	Zhengli Xu	Received

P-1287	HETROMBOPAG FOR ENHANCEMENT OF PLATELET ENGRAFTMENT IN PATIENTS WITH LYMPHOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	Cui Hao	Received

P-1288	UNMANIPULATED PERIPHERAL HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT IS AN EFFECTIVE CONSOLIDATIVE STRATEGY FOR HIGH-RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME	Fabio Serpenti	Received

P-1289	DECIPHERING THE CLONAL ARCHITECTURE IN SECONDARY ACUTE MYELOID LEUKEMIA AND DONOR CELL-DERIVED MYELODYSPLASTIC SYNDROME BY SINGLE-CELL MULTI-OMICS ANALYSIS	Ken-Hong Lim	Received

P-1291	REAL-WORLD DATA OF LONG-TERM SURVIVALS IN PATIENTS WITH MANTLE CELL LYMPHOMA WHO UNDERWENT STEM CELL TRANSPLANTATION	Dong Won Baek	Received

P-1295	ADVANTAGE OF FIRST-LINE TDM-DRIVEN USE OF INFLIXIMAB FOR TREATING ACUTE INTESTINAL AND LIVER GVHD IN CHILDREN: A PROSPECTIVE, SINGLE-CENTER STUDY.	Daniela Nistico´	Received

P-1296	THE LONG-TERM STRUCTURAL CHANGE OF THE GUT MICROBIOTA TRIGGERED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Akihisa Hino	Received

P-1299	OUTCOMES OF YOUNG ADULTS (AGED =40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT	Oren Pasvolsky	Received

P-1303	DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	Oren Pasvolsky	Received

P-1304	TREATMENT WITH COMBINATION OF RITUXIMAB AND INTRAVENOUS G GLOBULIN IS EFFECTIVE IN PROMOTING ENGRAFTMENT IN DONOR SPECIFIC ANTIBODY POSITIVE PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANT	Yuyan Shen	Received

P-1305	NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.	Idanna Innocenti	Received

P-1306	IMPACT OF HLA DISPARITY ON THE RISK OF OVERALL MORTALITY IN PATIENTS WITH EXTENSIVE CHRONIC GVHD	Shigeo Fuji	Received

P-1308	RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS	Erlie Jiang	Received

P-1309	THE DIRECT HEALTHCARE BURDEN ASSOCIATED WITH CHRONIC GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN ENGLAND: A REAL-WORLD EVIDENCE ANALYSIS	Daniele Avenoso	Received

P-1311	LONG-TERM SAFETY AND EFFICACY OF EXTRACORPOREAL PHOTOPHERESIS AS EARLY SECOND-LINE TREATMENT FOR PATIENTS WITH STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.	Eleni Papchianou	Received

P-1312	CHARACTERISTICS OF MEMBRANOUS NEPHROPATHY AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Hui Zhang	Received

P-1313	LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY	Chen Mei	Received

P-1315	THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION	Georg-Nikolaus Franke	Received

P-1318	CLOSTRIDIUM BUTYRICUM MIYAIRI 588 CONTRIBUTES TO THE MAINTENANCE OF INTESTINAL MICROBIOTA DIVERSITY EARLY AFTER HEMATOPOIETIC CELL TRANSPLANTATION.	Kentaro Fukushima	Received

P-1319	TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT	Anjali Cremer	Received

P-1322	EFFECTS OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) FOR PRIMARY GRAFT FAILURE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR	Jianyun Liao	Received

P-1323	THE PROGNOSIS AND COMPLICATIONS OF PATIENTS WITH PRE-TRANSPLANT LIVER DYSFUNCTION	Yukiko Misaki	Received

P-1324	EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA	Lidan Zhu	Received

P-1325	EFFICACY AND SAFETY OF HEROMBOPAG FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Huanfeng Liu	Received

P-1326	HEMATOPOIETIC STEM/PROGENITOR CELLS ORIGINATING FROM EXTRAEMBRYONIC ARTERIAL VESSELS ARE THE MAJOR CONTRIBUTORS TO MOUSE FETAL LYMPHO-MYELOPOIESIS	Emanuele Azzoni	Received

P-1329	REGIONAL COMPARTMENTALIZATION OF THE BONE MARROW STROMA IS IMPORTANT FOR RESPONSES TO INFLAMMATION AND CANCER	James Swann	Received

P-1331	DISTINCT REACTIVITY TO ENVIRONMENTAL FACTORS OF YS VERSUS HSC DERIVED PROGENITORS DICTATE HEMATOPOIESIS IN THE MOUSE FETAL LIVER	Francisca Soares-Da-Silva	Received

P-1337	IDENTIFICATION OF CLONAL HEMATOPOIESIS DRIVER MUTATIONS THROUGH IN SILICO SATURATION MUTAGENESIS	Santiago Demajo	Received

P-1338	VASCULARIZED BONE MARROW-ON-CHIP TO STUDY VASCULAR ABERRATION IN HEMATOPOIETIC DISEASES	Diana Passaro	Received

P-1340	MONOCYTE-DRIVEN INFLAMMATION IN DNMT3A-MUTANT CLONAL HAEMATOPOIESIS ACUTE ST-ELEVATION MYOCARDIAL INFARCTION.	Sarah Mackie	Received

P-1341	LC3-ASSOCIATED PHAGOCYTOSIS IS IMPAIRED IN BONE MARROW MACROPHAGES DURING AGEING LEADING TO DEFECTIVE PHAGOCYTOSIS AND ACCUMULATION OF APOPTOTIC DEBRIS WITHIN THE BONE MARROW.	Katherine Hampton	Received

P-1345	EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML	Jacobien Hilberink	Received

P-1347	H3K36 HISTONE METHYLTRANSFERASE NSD3 FUNCTIONS AS A CRUCIAL EPIGENETIC REGULATOR OF ERYTHROPOIESIS	Arunim Shah	Received

P-1348	C3G CONTROLS MEGAKARYOCYTE INFLUENCE ON MYELOID COMMITMENT OF HEMATOPOIETIC STEM CELLS UPON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION.	Óscar Herranz	Received

P-1349	EXTRACELLULAR ATP CONTRIBUTES TO ERYTHROPOIESIS-SUPPORTIVE MICROENVIRONMENT UNDER CHRONIC STRESS CONDITIONS	Sanja Momcilovic	Received

P-1350	M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS	Katerina Miari	Received

P-1352	BONE MARROW MORPHOLOGY DIAGNOSTIC ENVIRONMENT USING YOLO/RESNET ARTIFICIAL INTELLIGENCE MODEL	Matjaz Sever	Received

P-1354	CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.	Nawid Albinger	Received

P-1355	DELIVERY OF THERAPEUTIC RNA TO THE BONE MARROW IN MULTIPLE MYELOMA USING CD38-TARGETED LIPID NANOPARTICLES	Dana Tarab-Ravski	Received

P-1356	CD84-TARGETED CART-CELL THERAPY: A NOVEL STRATEGY FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES	Nela Klein González	Received

P-1359	TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES	Karan Chohan	Received

P-1361	SLEEPING BEAUTY PLATFORM FOR ENGINEERING CAR-CIK CELLS TOWARD A MULTI-TARGETING STRATEGY IN B-ALL	Alex Moretti	Received

P-1364	PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED / REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)	Anil Kamat	Received

P-1365	HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS	Anne Kaiser	Received

P-1366	SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T-CELL ACTIVITY AGAINST LARGE B-CELL LYMPHOMA	Patrick Reville	Received

P-1369	HDAC INHIBITION INVOLVES CD26 EXPRESSION ON MULTIPLE MYELOMA CELLS VIA THE C-MYC/SP1-MEDIATED PROMOTER ACTIVATION AND OVERCOMES THERAPEUTIC RESISTANCE BY HUMANIZED ANTIBODY	Hiroko Nishida	Received

P-1371	COMPARISON OF DIFFERENT METHODS FOR GENETIC CORRECTION OF GRISCELLI SYNDROME TYPE II-DERIVED STEM CELLS	Özgür Dogus Erol	Received

P-1372	NON-MYELOTOXIC CHEMICALS AS A PREPARATORY REGIMEN FOR HEMATOPOIETIC STEM CELL GENE THERAPY	Mehmet Emin Seker	Received

P-1373	UNCOVERING UPSIDES AND PITFALLS OF BASE AND PRIME EDITING IN HEMATOPOIETIC STEM CELLS	Martina Fiumara	Received

P-1375	VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS	Darina Ocadlikova	Received

P-1377	TRANSCRIPTOME-WIDE ANALYSIS OF T CELLS DURING EX VIVO EXPANSION AS PER CURRENT CAR T CELL MANUFACTURING PROTOCOL REVEALS SPECIFIC CHANGES IN T CELL SIGNALING AND HOMING	Harish Sudarsanam	Received

P-1382	CIRCULATING CAR-T CELLS MONITORING OF KINETICS AND EXHAUSTION MARKERS AS PREDICTIVE FACTORS IN B-CELL MALIGNANCIES	Belén Sierro Martínez	Received

P-1388	EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE	Sylvain Choquet	Received

P-1391	VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED / REFRACTORY CD19+ NON-HODGKIN LYMPHOMA	Nuria Martinez-Cibrian	Received

P-1395	PENTAVALENT-SPECIFIC T-CELLS POST HAPLO-IDENTICAL TRANSPLANTATION FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS	Zoi Boussiou	Received

P-1397	THIRD-PARTY MULTIVIRUS-SPECIFIC T CELLS FOR THE TREATMENT OF REFRACTORY VIRAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	Koray Yalcin	Received

P-1398	AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA	Nico Gagelmann	Received

P-1399	INITIAL CLINICAL RESULTS OF EUPLAGIA-1, A PHASE 1/2 TRIAL OF POINT-OF-CARE MANUFACTURED GLPG5201 IN R/R CLL/SLL WITH OR WITHOUT RICHTER´S TRANSFORMATION	Julio Delgado	Received

P-1400	THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE	Mika Geva	Received

P-1401	IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING-BASED ANALYSIS.	Marina Gómez-Llobell	Received

P-1405	IN-DEPTH GENOME INTEGRITY EVALUATION AND GMP-COMPLIANT MANUFACTURING OF HDR GENE EDITED CD4+ T CELLS FOR THE TREATMENT OF HYPER IGM 1	Daniele Canarutto	Received

P-1406	SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES	Zhengzheng Fu	Received

P-1407	REMOTE MONITORING OF CAR T-CELL TREATED PATIENTS BY A SPECIALIZED NURSE TO DETECT AND MANAGE LATE COMPLICATIONS: REPORT OF THE CARAMA PROGRAM	Fanny Colin	Received

P-1408	UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	Nicolas Boissel	Received

P-1409	PHASE-2 STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A) FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T WITH FRACTIONATED INFUSIONS FOR PATIENTS WITH RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY	Anil Kamat	Received

P-1412	CLINICIAN LED NUTRITIONAL ASSESSMENT AND PRE-OPTIMISATION OF PATIENTS UNDERGOING CAR-T CELL THERAPY	Frances Seymour	Received

P-1414	CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY	Shota Yokoyama	Received

P-1415	CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS	Vladan Vucinic	Received

P-1418	DETERMINANTS OF HAEMOGLOBIN IN SICKLE CELL DISEASE PATIENTS IN SUB-SAHARAN AFRICA: MAJOR IMPACT OF THE NATIVE COUNTRY AND INDEPENDENT EFFECTS OF INFLAMMATION AND HAEMOLYSIS.	Marica Rossi	Received

P-1419	A SINGLE CENTRE PERSPECTIVE ON PREGNANCY OUTCOMES AND SICKLE CELL COMPLICATIONS IN WOMEN ON HYDROXYCARBAMIDE PERI-CONCEPTION.	Maria Gregori	Received

P-1421	THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CEREBRAL PERFUSION AND OXYGEN METABOLISM IN PATIENTS WITH SICKLE CELL DISEASE	Liza Afzali-Hashemi	Received

P-1422	PREVALENCE AND RISK FACTORS FOR RETINOPATHY IN SICKLE CELL DISEASE	Kate Gardner	Received

P-1424	ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE	Myrthe Van Dijk	Received

P-1427	RARE ANAEMIA DISORDERS EUROPEAN EPIDEMIOLOGICAL PLATFORM (RADEEP): DISTRIBUTION OF PATIENTS AFFECTED BY RADS IN EUROPE	Maria Del Mar Mañú Pereira	Received

P-1428	PREDICTORS OF VOC RATE DURING LONG-TERM FOLLOW-UP OF PATIENTS WITH HBSS IN A NEWBORN COHORT STUDY	Muriel Ramalli	Received

P-1429	IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM	Chiara Federici	Received

P-1430	EPIDEMIOLOGY AND TREATMENT OF SICKLE CELL DISEASE ASSOCIATED VASO-OCCLUSIVE CRISES IN INPATIENT AND EMERGENCY CARE SETTINGS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS	Ami Patel	Received

P-1431	ACCURATE CELL-FREE HEME DOSAGE IN PLASMA CORRELATES WITH ANEMIA, HEMOLYSIS AND SICKLE CELL NEPHROPATHY SEVERITY	Laura Bencheikh	Received

P-1433	POSITRON EMISSION TOMOGRAPHY IMAGING OF VLA-4 AS A NEW BIOMARKER OF VASO-OCCLUSION IN SICKLE CELL DISEASE	Enrico Novelli	Received

P-1434	THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE, BARRIERS TO MEDICATION ADHERENCE, AND QUALITY OF LIFE IN SICKLE CELL DISEASE	Kathryn King	Received

P-1436	AGEING IMPACTS HYDROXYCARBAMIDE DOSING IN PATIENTS WITH SICKLE CELL DISEASE	Isabelle Doss	Received

P-1437	ASSESSING THE ROLE OF MICRORNAS IN HYDROXYUREA -MEDIATED HBF INDUCTION IN HAEMOGLOBINOPATHIES PATIENTS	Neha Kargutkar	Received

P-1438	L-GLUTAMINE: A NOVEL AND EFFECTIVE THERAPEUTIC TOOL FOR VOC REDUCTION IN SCD	Pablo Bartolucci	Received

P-1441	REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.	Kim Summers	Received

P-1442	PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY	Sherif Badawy	Received

P-1444	AVASCULAR NECROSIS IN PATIENTS WITH SICKLE CELL DISEASE: A RETROSPECTIVE ANALYSIS AT A SPECIALIST HAEMOGLOBINOPATHY CENTRE	Niamh Loughran	Received

P-1445	THE IMPACT OF ILLNESS PERCEPTION AND STIGMA ON PATIENT-REPORTED OUTCOMES IN SICKLE CELL DISEASE	Savannah Winkler	Received

P-1446	HYDROXYUREA AND LIMB ULCERS: IS IT WORTH SUSPENDING? RETROSPECTIVE COHORT STUDY OF BRAZILIAN ADULT PATIENTS WITH SICKLE CELL DISEASE	Bruno Benites	Received

P-1448	CHARACTERISATION OF QUALITY OF LIFE-LINKED PATIENT-REPORTED OUTCOMES THROUGH A DIGITAL AND CONTINUOUS REMOTE MONITORING ECOSYSTEM IN SICKLE CELL DISEASE.	Kim Summers	Received

P-1449	SAFETY PROFILE OF KETOROLAC CONTINUOUS INFUSION IN SICKLE CELL RELATED ACUTE VASO-OCCLUSIVE CRISIS	Valeria Maria Pinto	Received

P-1451	PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX : RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY	Isabelle Thuret	Received

P-1454	CLINICAL DETERMINANTS OF CARDIAC IRON IN REGULARLY TRANSFUSED THALASSEMIA INTERMEDIA PATIENTS	Antonella Meloni	Received

P-1455	THROMBOEMBOLIC EVENTS IN SPLENECTOMISED VERSUS NON-SPLENECTOMISED THALASSEMIA PATIENTS: A META-ANALYSIS OF OBSERVATIONAL STUDIES	Tsampika Vasileia Kalamara	Received

P-1456	MULTIPARAMETRIC CMR AND CARDIAC COMPLICATIONS IN THALASSEMIA INTERMEDIA	Antonella Meloni	Received

P-1457	MOTION ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA INTERMEDIA PATIENTS	Antonella Meloni	Received

P-1459	CHRONIC HEPATITIS C VIRUS INFECTION IS ASSOCIATED WITH AN INCREASED RISK OF CARDIAC COMPLICATIONS IN THALASSEMIA MAJOR	Antonella Meloni	Received

P-1460	INDUCTION OF FETAL HEMOGLOBIN BY TARGETED DELETION OF ZINC FINGER DOMAIN WITHIN BCL11A GENE USING CRISPR-CAS9 TECHNOLOGY	Afsar Mian	Received

P-1461	INFLAMMATORY AND SENESCENCE-ASSOCIATED MEDIATORS AFFECT THE PERSISTENCE OF HUMORAL RESPONSE TO COVID-19 MRNA VACCINATION IN TRANSFUSION-DEPENDENT BETA-THALASSEMIC PATIENTS	Chiara Agrati	Received

P-1468	PIEZO1 GAIN-OF-FUNCTION VARIANTS ACCOUNT FOR STRESSED ERYTHROPOIESIS BY ALTERING APOPTOSIS, HYPOXIA CELL RESPONSE, AND GLYCOLYSIS	Barbara Eleni Rosato	Received

P-1470	IDENTIFICATION OF THE PRO20THR NOVEL VARIANT IN CDIN1 GENE ALLOWED EXPLORING THE BIOLOGICAL PROCESSES IMPAIRED IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE I	Roberta Marra	Received

P-1472	COINHERITANCE OF PIEZO1 VARIANTS AND MULTI-LOCUS RED BLOOD CELL DEFECTS ACCOUNT FOR THE SYMPTOMATIC PHENOTYPE IN BETA-THALASSEMIA CARRIERS.	Valeria Maria Pinto	Received

P-1473	CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL	Hanny Al-Samkari	Received

P-1477	MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL	Rachael F. Grace	Received

P-1479	COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY	Dagmar Pospísilová	Received

P-1481	SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA	Myrthe Van Dijk	Received

P-1482	RECOMBINANT ERYTHROPOIETIN IN AUTOIMMUNE HEMOLYTIC ANEMIA WITH INADEQUATE RETICULOCYTOSIS: A SINGLE CENTER PROSPECTIVE STUDY	Giacinto Luca Pedone	Received

P-1484	THE DANISH SCREENING PROGRAM FOR HEMOGLOBINOPATHIES: A 16-YEAR REVIEW	Esther Gravholt	Received

P-1493	DIAGNOSTIC ACCURACY OF AN AUTOMATED MAGNETIC RESONANCE IMAGE ANALYSIS SYSTEM FOR THE RAPID EVALUATION OF LIVER IRON CONCENTRATION IN PATIENTS WITH HFE RELATED HEMOCHROMATOSIS.	Tim St Pierre	Received

P-1494	EFFECT OF IRON DEFICIENCY ANEMIA ON PROPRIOCEPTION IN ADULT WOMEN	Ines Mezghani	Received

P-1495	A PHASE III, RANDOMISED CONTROLLED SAFETY, EFFICACY AND COST EFFECTIVENESS TRIAL OF INTRAVENOUS IRON ISOMALTOSIDE (I3R) AND FERRIC CARBOXY MALTOSE (FERIUMR) IN SUBJECTS WITH IRON DEFICIENCY ANEMIA	Harikrishnan P	Received

P-1497	MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED	Eduard Van Beers	Received

P-1502	CHARACTERIZATION OF THE MUTATION PATTERN OF GENES ASSOCIATED WITH IRON OVERLOAD IN A BRAZILIAN POPULATION	Ana Carolina Toreli	Received

P-1506	TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS	Kristine Frerichs	Received

P-1507	A PREDICTIVE MODEL OF HERPES ZOSTER AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: VZV REACTIVATION AFTER ANTIVIRAL PROPHYLAXIS DISCONTINUATION	Xiao-Hui Zhang	Received

P-1509	CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY	Francesco Autore	Received

P-1514	MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY	Jon Salmanton-García	Received

P-1518	INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Edward R Scheffer Cliff	Received

P-1520	PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601	Isao Yoshida	Received

P-1521	IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT	Jon Salmanton-García	Received

P-1522	PERIPHERAL BLOOD SMEARS DISTINGUISH INFECTIVE FEVER AFTER CAR-T THERAPY	Shaolong He	Received

P-1523	IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA	Sabine Haggenburg	Received

P-1526	THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS	Takahide Ara	Received

P-1527	ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS	Zhangjie Chen	Received

P-1528	DIAGNOSTIC AND THERAPEUTIC EVALUATION OF CARBAPENEM-RESISTANT ORGANISMS BLOODSTREAM INFECTION FROM GUT COLONIZATION IN HSCT PATIENTS UNDERWENT CARBAPENEMASE GENES GUIDED THERAPY	Qian Chenjing	Received

P-1530	CORTICOSTEROIDS FOR INFLAMMATORY RESPONSES DURING INDUCTION CHEMOTHERAPY IN MYELOID MALIGNANCIES ARE NOT ASSOCIATED WITH INCREASED INCIDENCE OF INVASIVE FUNGAL INFECTIONS	Suzanne Van Dorp	Received

P-1531	TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE	Luca Pezzullo	Received

P-1533	A PROGNOSTIC MODEL FOR PATIENTS WITH SEPTIC SHOCK AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Hui Zhang	Received

P-1534	MRNA-1273 SARS-COV-2 VACCINE IN RECENTLY TRANSPLANTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: CELLULAR AND HUMORAL IMMUNE RESPONSES AND BOOSTER EFFECT	Nil Albiol	Received

P-1535	ASSESSMENT OF COLONIZATION AND INFECTION EPIDEMIOLOGY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A PROSPECTIVE MULTI-CENTER STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG).	Agnieszka Pluta	Received

P-1536	SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY	Tom Reuvekamp	Received

P-1537	MORTALITY AND BURDEN OF POST-COVID-19 SYNDROME HAVE REDUCED WITH TIME ACROSS SARS-COV-2 VARIANTS IN HAEMATOLOGY PATIENTS	John Willan	Received

P-1538	MULTIDRUG RESISTANT BACTERIAL COLONIZATION AND RELATED BLOODSTREAM INFECTIONS IN FEBRILE HAEMATOLOGIC PATIENTS: EPIDEMIOLOGY AND OUTCOME	Chiara Cattaneo	Received

P-1539	INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES	Daniela Clerici	Received

P-1541	CONVALESCENCE NEW LIQUID COOLING THERAPY ON PREVENTION AND TREATMENT OF CHEMOTHERAPEUTIC ORAL MUCOSITIS	Yang He	Received

P-1543	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THAT NEED VASOACTIVE SUPPORT – SINGLE CENTER STUDY	Roy Vitkon	Received

P-1544	IMPACT OF SARS-COV 2 INFECTION, IN TREATED NHL-B AND HD, AFTER VACCINATION AND PREVENTIVE THERAPY WITH ANTIBODIES: OUR EXPERIENCE	Luca Pezzullo	Received

P-1545	INCIDENCE AND OUTCOMES IN PATIENTS WITH INVASIVE CEREBRAL ASPERGILLOSIS RECEIVING IBRUTINIB TREATMENT: A RETROSPECTIVE ANALYSIS ACROSS FIVE HOSPITALS IN EAST ANGLIA AND SOUTH YORKSHIRE, ENGLAND	Victor Ling	Received

P-1546	HEMATOLOGIC ADVERSE EVENTS AFTER COVID-19 VACCINATION IN THE PHILIPPINES: A NATIONAL DATABASE STUDY	Flordeluna Mesina	Received

P-1547	CLINICAL CHARACTERISTICS OF PATIENTS WITH PROLONGED VIRAL SHEDDING OF OMICRON VARIANT IN HAEMATOLOGICAL DISEASE	Daisuke Ikeda	Received

P-1549	HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.	Francesca Farina	Received

P-1550	HAEMATOLOGICAL PREDICTORS OF POOR OUTCOME AMONG COVID-19 PATIENTS ADMITTED TO AN INTENSIVE CARE UNIT OF A SOUTH AFRICAN TERTIARY HOSPITAL	Zivanai Cuthbert Chapanduka	Received

P-1555	COVID-19 INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A SINGLE-CENTRE SURVEY DURING THE LATEST OMICRON WAVE IN CHINA	Xiaolu Zhu	Received

P-1556	EVALUATION OF THE USEFULNESS OF INTERFERON-GAMMA RELEASE ASSAY FOR THE DETECTION OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTIONS IN PATIENTS WHO UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANTATION	Sungnam Lim	Received

P-1557	A STUDY ON THE IMMUNOGENICITY OF COVID-19 VACCINE IN PATIENTS WITH HEMATOLOGIC MALIGNANCY	Flordeluna Mesina	Received

P-1558	PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS	Andrea Duminuco	Received

P-1559	ASSOCIATION BETWEEN TNF-? LEVELS AND FALCIPARUM MALARIA PANCYTOPENIA AMONG SUDANESE CHILDREN	Khalid Abdelsamea Mohamedahmed	Received

P-1562	THE FIRST TWO YEARS OF THE EUROPEAN VACCELERATE VOLUNTEER REGISTRY	Jon Salmanton-García	Received

P-1563	REMDESIVIR USE IN SEVERE AND CRITICAL COVID-19 PATIENTS MIGHT BE ASSOCIATED WITH LOWER INCIDENCE OF ARTERIAL THROMBOTIC EVENTS	Marko Lucijanic	Received

P-1568	NATURAL HISTORY OF CHRONIC ISOLATED NEUTROPENIA: A SINGLE CENTER OBSERVATIONAL STUDY	Bruno Fattizzo	Received

P-1569	HERPES ZOSTER VACCINATION IN HEMATOLOGY. A SINGLE CENTER EXPERIENCE.	Natalia De Las Heras Rodriguez	Received

P-1572	COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.	Daniele Sannipoli	Received

P-1579	GENOTYPE-PHENOTYPE CORRELATION IN THREE CASES OF PREGNANCY ONSET CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (CTTP): A SINGLE CENTRE STUDY	Francesca Schieppati	Received

P-1582	A COMPARISON OF TRANSFUSION REACTIONS BETWEEN PRESTORAGE AND POSTSTORAGE LEUKOREDUCED APHERESIS PLATELETS: A PROPENSITY-SCORE MATCHING ANALYSIS	Sheng-Hsuan Chien	Received

P-1583	TRANSFUSIONS IN AUTOIMMUNE HEMOLYTIC ANEMIA: FREQUENCY AND CLINICAL SIGNIFICANCE OF ALLOIMMUNIZATION	Francesco Versino	Received

P-1584	PREVELANCE OF ABO DISCPRENACIES AND ITS CLASSIFACTION IN BLOOD DONORS AT REGIONAL BLOOD CENTRE, KARACHI.	Samra Waheed	Received

P-1588	LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY	Pramod Mistry	Received

P-1591	IMPACT OF COVID-19 ON THE EVOLUTION OF PRE-EXISTING PRIMARY IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE OBSERVATIONAL STUDY	Haixia Fu	Received

P-1594	BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL	Peng Zhao	Received

P-1595	ACTIVATION OF CHAPERONE-MEDIATED AUTOPHAGY REDUCES NLRP3 AND PLATELET CLEARANCE IN IMMUNE THROMBOCYTOPENIA	Yitong Xu	Received

P-1596	EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL	Jie Jin	Received

P-1597	COMPLEMENT ACTIVATION ON MSCS REGULATE MEGAKARYOPOIESIS BY INTERLEUKIN-35 AND ITS RECEPTOR IL-12R?2/GP130 IN IMMUNE THROMBOCYTOPENIA	Xiaolu Zhu	Received

P-1598	UTILITY OF ´OPEN/CLOSED´ ADAMTS13 IN MONITORING IMMUNE TTP	Nithya Prasannan	Received

P-1600	USE OF RITUXIMAB PLUS STANDARD OF CARE FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Ali Eshaghpour	Received

P-1601	PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY	Simone Zoletto	Received

P-1603	EFFICACY AND SAFETY OF BRUTON´S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP	Xiao-Hui Zhang	Received

P-1605	IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA IN OLDER PATIENTS: RESULTS FROM THE SPANISH TTP REGISTRY (REPTT)	Inés Gómez Seguí	Received

P-1606	PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS: REAL WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY	Charalampos Pontikoglou	Received

P-1609	CAPLACIZUMAB THERAPY IN OLDER PATIENTS (=60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY	Javier De La Rubia	Received

P-1610	VALIDATION AND CLINICAL CHARACTERISTICS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND EVANS SYNDROME DIAGNOSES IN NATIONWIDE DANISH HEALTH REGISTERS	Dana Lawrie	Received

P-1611	EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION:A MULTICENTER, RANDOMIZED PHASE III TRIAL	Liangjie Zhong	Received

P-1613	REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.	Guillaume Moulis	Received

P-1614	TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB	María Eva Mingot Castellano	Received

P-1617	A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A	Feng Xue	Received

P-1618	REAL-WORLD DATA ON EMICIZUMAB: CORRELATION BETWEEN DRUG PLASMA LEVELS, GLOBAL PROCOAGULANT STATUS AND SPONTANEOUS JOINT ANNUALIZED BLEEDING RATE	Adrián Montaño	Received

P-1621	INCIDENCE, RISK FACTORS AND MORTALITY ASSOCIATED WITH MAJOR BLEEDING EVENTS IN HOSPITALIZED COVID-19 PATIENTS, TERTIARY CENTER EXPERIENCE	Marko Lucijanic	Received

P-1623	LOW LEVELS OF 25(OH) VITAMIN D IN ADULT PRIMARY ITP PATIENTS	Jasmin Rast	Received

P-1625	CLINICAL AND LABORATORY CHARACTERISTICS OF ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EASTERN AUSTRIA	Jasmin Rast	Received

P-1626	A SINGLE-CENTER EXPERIENCE IN INCREASING FACTOR VIII LEVELS TO ACHIEVE ZERO BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A.	Adrián Montaño	Received

P-1628	FACTOR XI DEFICIENCY IN CHINESE FEMALE PATIENTS: RESULTS FROM A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY	Xiyan Wang	Received

P-1629	DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE	Adrián Montaño	Received

P-1630	A 2022 CROSS-NATIONAL SURVEY OF PEOPLE LIVING WITH HAEMOPHILIA DURING THE COVID-19 PANDEMIC: VIEWS ON VACCINATION- AND INFECTION-RELATED RISKS	Ana Boban	Received

P-1633	OUTCOME OF SURGICAL INTERVENTIONS IN PATIENTS WITH HAEMOPHILIA A AND B TREATED WITH EXTENDED HALF-LIFE (EHL) FACTOR CONCENTRATES IN A SINGLE CENTRE	Ines Vaide	Received

P-1635	DETERMINATION OF THE EFFECTIVE CONCENTRATION OF TRANEXAMIC ACID NEUTRALIZING IN AN IN VITRO UROKINASE INDUCED HYPERFIBRINOLYTIC MODEL USING A GLOBAL FIBRINOLYTIC CAPACITY ASSAY	Anton Evenepoel	Received

P-1638	CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IS A RISK FACTOR FOR PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH COVID-19.	Federico Mario Aletti	Received

P-1640	REAL-WORLD SUPPORTIVE EVIDENCE FOR THE 4D-DVT ALGORITHM: ADJUSTING D-DIMER THRESHOLDS FOR INITIAL AND FOLLOW-UP IMAGING OF PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS BY CLINICAL PROBABILITY	John Willan	Received

P-1641	RECURRENT VENOUS THROMBOEMBOLISMS AND ANTICOAGULATION COMPLICATIONS; A PROSPECTIVE STUDY.	Teymur Nasibov	Received

P-1642	CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL ARE ASSOCIATED WITH INCREASED NETOSIS IN PATIENTS WITH CARDIOVASCULAR EVENTS	Olivier Mansier	Received

P-1645	IMPACT OF VON WILLEBRAND FACTOR AND ADAMTS13 ON CARDIOVASCULAR COMPLICATIONS AND BLEEDING IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND NORMAL SINUS RHYTHM CONTROLS: 10 YEARS FOLLOW UP.	Waldemar Wysokinski	Received

P-1646	A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON PRIMARY AMBULATORY THROMBOPROPHYLAXIS (PATP) IN PATIENTS WITH LYMPHOMA RECEIVING CHEMOTHERAPY	Thura Htut	Received

P-1648	THE RELATION BETWEEN THE SECONDARY STRUCTUE OF HEMOGLOBIN AND ENHANCED HYPOXIA-INDUCED ATP RELEASE FROM RED BLOOD CELLS IN APOE/LDLR DOUBLE-DEFICIENT MICE	Fatih Celal Alcicek	Received

P-1650	CT PULMONARY ANGIOGRAPHY UTILIZATION IN THE EMERGENCY DEPARTMENT: DIAGNOSTIC YIELD AND ADHERENCE TO CURRENT GUIDELINES	Abdulrahman Al Raizah	Received

P-1651	IMPACT OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) AND MACROPHAGE ACTIVATION IN THE THROMBOTIC EVENTS IN COVID-19 PATIENTS	Irene Serrano-Gonzalo	Received

P-1652	SAFETY OF DOACS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	Lucy Zhao	Received

P-1653	INFLAMMATION MEDIATED THROMBUS FORMATION IN LYMPHOMAS	Olivera Mitrovic Ajtic	Received

P-1654	IS THERE REALLY AN INCREASED RISK IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME UNDERGOING TO INVASIVE PROCEDURES?	Rocio Camacho	Received

P-1655	DEEP VENOUS THROMBOSIS IN PATIENT WITH ATRESIA OF INFERIOR VENA CAVA AND RIGHT KIDNEY HYPOPLASIA (KILT SYNDROME): CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE	Nikola Pantic	Received

P-1656	PROGRESSIVE WORSENING OF PROTHROMBOTIC PROFILE IN PATIENTS WITH AGGRESSIVE LYMPHOMA ON CHEMOTHERAPY	Ihosvany Fernández Bello	Received

P-1657	CANCER-ASSOCIATED NON-BACTERIAL THROMBOTIC ENDOCARDITIS AFFECTING RIGHT HEART VALVES AS POTENTIAL CAUSE OF PULMONARY EMBOLISM	Ewa Wysokinska	Received

P-1659	STUDY AND POSSIBLE DIAGNOSIS OF PATIENTS WITH THROMBOTIC MICROANGIOPATHIES WHO PRESENT ADAMTS13 ACTIVITIES BETWEEN 5-10%	Marta Molina-Pérez	Received

P-1661	THROMBOSIS AND BLEEDING IN CANCER PATIENTS WITH COVID-19: A DIFFICULT BALANCE	Abdulrahman Al Raizah	Received

P-1662	STUDY OF THE DEVELOPMENT AND INVOLVEMENT OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) IN VASCULAR COMPLICATIONS IN LYSOSOMAL DISORDERS	Irene Serrano-Gonzalo	Received

P-1664	WHICH FACTORS DO IMPACT IN OPTIMAL ANTICOAGULATION IN ANTIPHOSPHOLIPID SYNDROME?	Juan Luis Ontiveros-Austria	Received

P-1665	USE OF DOACS IN THE MANAGEMENT OF UPPER EXTREMITY DEEP VENOUS THROMBOSIS; A SYSTEMATIC REVIEW	Sarah Ge	Received

P-1666	THE BURDEN OF VENOUS THROMBOEMBOLISM AND THE CHALLENGES IN DELIVERING ADEQUATE CARE IN THE SETTING OF POVERTY, HOMELESSNESS, AND SOCIAL EXCLUSION: A SINGLE CENTRE CROSS-SECTIONAL STUDY	Ellen O´Rourke	Received

P-1667	ATTRIBUTES OF RANDOMIZED CONTROLLED TRIALS AND THEIR ASSOCIATIONS WITH FUNDING SOURCE IN VENOUS THROMBOEMBOLISM PROPHYLAXIS FOR PATIENTS WITH CANCER: A BIBLIOGRAPHICAL ANALYSIS	Lucy Zhao	Received

P-1669	DIRECT ORAL ANTICOAGULANTS VS LOW MOLECULAR WEIGHT HEPARIN IN THE MANAGEMENT OF PATIENTS WITH PRIMARY OR METASTATIC BRAIN TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS	Wenhui Yu	Received

P-1671	CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA	Niels Abildgaard	Received

P-1674	PAP SCORE (PALLIATIVE PROGNOSTIC SCORE) ESTIMATES SHORT-TERM SURVIVAL IN A COHORT OF HEMATOLOGICAL PATIENTS	Davide Facchinelli	Received

P-1676	RISK OF DEMENTIA IN OLDER PATIENTS TREATED WITH CHEMOTHERAPY FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY	Eva Maksten	Received

P-1677	DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS	Pramila Krishnamurthy	Received

P-1678	INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION	Briony Shaw	Received

P-1681	RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA	Jennifer Ahlstrom	Received

P-1682	HEALTH RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE: ARE WE SURE TO GET IT RIGHT? PATIENTS AND PARENTS MIGHT HAVE DIFFERENT OPINIONS.	Desiré Fantasia	Received

P-1683	THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA	Simone Oerlemans	Received

P-1686	LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY	Fabio Efficace	Received

P-1687	LIFE AFTER CAR T-CELLS : DO PATIENTS RECOVER A NORMAL LIFE?	Alya Perthus	Received

P-1688	LIVING WITH ACUTE LEUKEMIA: A GLOBAL SURVEY OF PATIENTS AND CARERS EXPERIENCE	Zack Pemberton-Whiteley	Received

P-1689	REAL-WORLD EVIDENCE OF USING TELEMEDICINE TO CAPTURE ELECTRONIC PROM IMPROVES QUALITY OF LIFE ASSESSMENT, HEALTHCARE RESOURCES MANAGEMENT AND OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA	Sergio Ramos	Received

P-1690	SHARED DECISION-MAKING IN MULTIPLE MYELOMA: DO PATIENTS, CAREGIVERS, AND PHYSICIANS SHARE THE SAME GOALS AND PREFERENCES?	Jennifer Ahlstrom	Received

P-1691	PALLIATIVE CARE IN HEMATOLOGICAL PATIENTS IS RELATED TO LESS AGGRESSIVE TREATMENT IN THE END-OF-LIFE, A RETROSPECTIVE STUDY.	Davide Facchinelli	Received

P-1695	REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING	Justin Puckett	Received

P-1697	CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB	Irina Murakhovskaya	Received

EHA2023 Hybrid Congress

June, 8-11 Frankfurt

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 08/06/2023 TO 08/06/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access